We seek to enter partnerships on programs where collaboration adds expertise and additional resources. The company has created strong partnerships in the past, both in CNS and infl ammation. Last year we strengthened our partnership with Lundbeck for nalmefene and made good progress with our novel CNS molecules at Pfi zer. We look forward to fostering additional relationships in the coming years for our novel VAP-1 antibody (to which Roche has an option) and ELB353 in COPD.
------
Updated March, 2010